Abstract
Background/Aims: Patients with recurrent hepatitis C are often treated with interferon-based therapy in an attempt to prevent cirrhosis requiring retransplantation. We describe our experience with 32 patients with recurrent HCV. Methodology: Patients were followed prospectively after starting pegylated interferon alfa-2a 180μg per week and ribavfrin 1000-1200mg per day. HCV ribonucleic acid (HCVRNA) was repeated at three months, end of treatment (EOT) and six months after EOT for patients HCVRNA negative at EOT. Results: There were 22 males and 10 females. 21 patients have completed treatment, six remain on therapy and five were intolerant. In an intention-to-treat analysis, sustained viral eradication occurred in 40.6% of patients. Fibrosis scores were worse in eight patients of whom six were sustained responders. Three of these patients developed decompensated liver disease. Two were successfully retransplanted and remain HCVRNA negative after a mean follow-up of 11 months. Conclusions: Pegylated interferon alpha-2a and ribavirin were well tolerated in this small series. Sustained HCV eradication occurred in at least 40.6% of patients but progressive fibrosis occurred in 75% of sustained responders. This suggests that mechanisms other than recurrent HCV may be responsible for cirrhosis in sustained responders who remain at risk of developing decompensated liver disease.
| Original language | English |
|---|---|
| Pages (from-to) | 561-565 |
| Number of pages | 5 |
| Journal | Hepato-Gastroenterology |
| Volume | 53 |
| Issue number | 70 |
| State | Published - Jul 2006 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Gastroenterology
Cite this
Impact of pegylated interferon alfa-2a and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C : An open-label series. / Mukherjee, Sandeep; Lyden, Elizabeth.
In: Hepato-Gastroenterology, Vol. 53, No. 70, 07.2006, p. 561-565.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Impact of pegylated interferon alfa-2a and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C
T2 - An open-label series
AU - Mukherjee, Sandeep
AU - Lyden, Elizabeth
PY - 2006/7
Y1 - 2006/7
N2 - Background/Aims: Patients with recurrent hepatitis C are often treated with interferon-based therapy in an attempt to prevent cirrhosis requiring retransplantation. We describe our experience with 32 patients with recurrent HCV. Methodology: Patients were followed prospectively after starting pegylated interferon alfa-2a 180μg per week and ribavfrin 1000-1200mg per day. HCV ribonucleic acid (HCVRNA) was repeated at three months, end of treatment (EOT) and six months after EOT for patients HCVRNA negative at EOT. Results: There were 22 males and 10 females. 21 patients have completed treatment, six remain on therapy and five were intolerant. In an intention-to-treat analysis, sustained viral eradication occurred in 40.6% of patients. Fibrosis scores were worse in eight patients of whom six were sustained responders. Three of these patients developed decompensated liver disease. Two were successfully retransplanted and remain HCVRNA negative after a mean follow-up of 11 months. Conclusions: Pegylated interferon alpha-2a and ribavirin were well tolerated in this small series. Sustained HCV eradication occurred in at least 40.6% of patients but progressive fibrosis occurred in 75% of sustained responders. This suggests that mechanisms other than recurrent HCV may be responsible for cirrhosis in sustained responders who remain at risk of developing decompensated liver disease.
AB - Background/Aims: Patients with recurrent hepatitis C are often treated with interferon-based therapy in an attempt to prevent cirrhosis requiring retransplantation. We describe our experience with 32 patients with recurrent HCV. Methodology: Patients were followed prospectively after starting pegylated interferon alfa-2a 180μg per week and ribavfrin 1000-1200mg per day. HCV ribonucleic acid (HCVRNA) was repeated at three months, end of treatment (EOT) and six months after EOT for patients HCVRNA negative at EOT. Results: There were 22 males and 10 females. 21 patients have completed treatment, six remain on therapy and five were intolerant. In an intention-to-treat analysis, sustained viral eradication occurred in 40.6% of patients. Fibrosis scores were worse in eight patients of whom six were sustained responders. Three of these patients developed decompensated liver disease. Two were successfully retransplanted and remain HCVRNA negative after a mean follow-up of 11 months. Conclusions: Pegylated interferon alpha-2a and ribavirin were well tolerated in this small series. Sustained HCV eradication occurred in at least 40.6% of patients but progressive fibrosis occurred in 75% of sustained responders. This suggests that mechanisms other than recurrent HCV may be responsible for cirrhosis in sustained responders who remain at risk of developing decompensated liver disease.
UR - http://www.scopus.com/inward/record.url?scp=33748658854&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33748658854&partnerID=8YFLogxK
M3 - Article
C2 - 16995462
AN - SCOPUS:33748658854
VL - 53
SP - 561
EP - 565
JO - Acta hepato-splenologica
JF - Acta hepato-splenologica
SN - 0172-6390
IS - 70
ER -